ReShape Lifesciences (RSLS, Financial) has been granted a Notice of Allowance by the U.S. Patent and Trademark Office for its patent application titled "High-Frequency Low Duty Cycle Patterns for Neural Regulation." This development is significant as it ensures patent protection for the innovation until August 4, 2037.
The patented Diabetes Neuromodulation system is a cutting-edge approach to managing Type 2 diabetes by utilizing proprietary vagus nerve block technology. This technology combines vagus nerve stimulation to effectively regulate blood glucose levels, offering a new avenue for treating a condition that often proves challenging despite existing medications, surgical techniques, and dietary measures.
ReShape's novel system administers targeted vagal nerve modulation, impacting signals to and from the liver and pancreas. It implements discontinuous high-frequency signals that intersperse micro- and millisecond pauses, creating an energy-efficient algorithm. This method essentially 'taps' the nerve with stimulation bursts, resulting in an effective blocking mechanism while consuming significantly less energy compared to traditional methods. The efficiency of this system facilitates the use of smaller batteries and longer intervals between charges, thereby enhancing the practicality and usability of the device.
The approval of this patent marks a milestone in ReShape Lifesciences’ efforts to provide innovative solutions in diabetes treatment, leveraging advanced technology for improved patient outcomes.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Reshape Lifesciences Inc (RSLS, Financial) is $1.00 with a high estimate of $1.00 and a low estimate of $1.00. The average target implies an upside of 222.89% from the current price of $0.31. More detailed estimate data can be found on the Reshape Lifesciences Inc (RSLS) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Reshape Lifesciences Inc's (RSLS, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
